Overactive bladder treatment market size in 2018, is $3.7 billion and is projected to reach revenue of $4.61 billion by 2025. Overactive bladder is the condition in which there is an uncontrollable need to urinate. OAB treatments include lifestyle changes, medications, Botox treatments, nerve simulation, and even surgery.
The market is estimated to grow at a CAGR of 3.1% during the forecast period 2019-2025 owing to the rising prevalence of urinary incontinence among women and geriatric population. FDA drug approvals are increasing especially for generic drugs and this tends to drive the overactive bladder treatment market.
Companies are adopting various strategic alliances to expand in various regions. They are also developing new technology to reduce the symptoms and treat overactive bladder.
Pharmacotherapy – Segment Analysis
Initial treatments for urge incontinence include pelvic floor exercises, bladder training and behavioral methods. Anticholinergic treatments block the neurotransmission thus reducing the feeling of urgency. This segment is said to occupy major share but its demand is decreasing as these drugs cause many side effects. Botox or Botulinum toxin helps strengthen the bladder. Its dose ranges from 50-300 units and has to be injected repeatedly as the toxin dose wears off. The Botox segment is said to have the fastest growth rate with CAGR 2.9% and there has been an increase in use of Botox among patients who do not prefer surgery or oral medication.
Download Sample Report @ https://www.industryarc.com/pdfdownload.php?id=505699
Disease – Segment Analysis
Idiopathic overactive bladder is to account for the major share among diseases that cause OAB. This is owing to the rise in OAB among women post menopause or pregnancy as well as among the geriatric population. Urinary tract infections are also known to cause OAB as this condition increases activation of the bladder muscles. Diseases such as diabetes insipidus results in excessive urination which is often misunderstood as OAB. And such similar symptoms result in oversight of the major disease.
Geography – Segment Analysis
North America accounts for largest Overactive bladder treatment market share with 48% in 2018. This is owing to the high prevalence of this disease among Americans. As per the National Association for Continence, OAB affects an estimated 33 million people in the USA alone. Thus the treatment demand for this is likely to be high. However, Asia Pacific is expected to have the fastest growth as the prevalence of OAB is rising and also due to the increasing awareness on OAB among the people.
Drivers – Overactive Bladder Treatment Market
Increase in Aging Population and rising OAB occurrence among women
Urinary or urge incontinence is the condition that results from delay in treatment of an overactive bladder. This is prevalent among women and older population. As per WHO – Integrated care for older people (2017), the prevalence of urinary incontinence is twice as high in older women as in older men. Thus a rise in the geriatric population coupled by diseases that are resultant from OAB are contributing to growth of OAB treatment market.
Increasing Drug Developments for Overactive Bladder Treatment
Many drugs are being developed for Overactive bladder treatment by various companies. They are focusing on combination therapies and drugs with minimal side effects. Drug approvals are also increasing due to the rising prevalence of overactive bladder. FDA is also increasing approvals on generic drugs thus also lowering the prices. This is because of new regulatory authorities by FDA to speed up drug approvals. This encourages competition and more companies come out with drugs.
Challenges – Overactive Bladder Treatment Market
Side Effects of Current Treatments
Anticholinergic drugs used for treatment of OAB have harmful side effects. These drugs interact with the brain or neural system and can result in memory loss, hallucinations, insomnia and other effects. Even Botox treatment have side effects like urinary tract infections. The side effects by these treatments tend to challenge the growth of the market.
Overactive Bladder Treatment Industry Outlook
Research & development along with strategic alliances are some of the key strategies adopted by players in the Overactive Bladder Treatment market. Overactive Bladder Treatment Market top 10 companies are Astellas Pharma Inc, Pfizer, Inc, Teva Pharmaceutical Industries Limited, Allergan, PLC, Mylan N.V, Hisamitsu Pharmaceutical Co., Inc, Sanofi, Aurobindo Pharma Limited, Johnson & Johnson, and Medtronic PLC.
The company, Triple W developed DFree, a wearable device for incontinence that can track the progression of bladder movements using a non-invasive ultrasonic sensor.
Overactive Bladder Treatment Market Research Scope:
The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. These provide the key market participants with the necessary business intelligence and help them understand the future of the Overactive Bladder Treatment Market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats.
IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to firstname.lastname@example.org to discuss more about our consulting services.